These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 32677196

  • 1. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
    Zhou Y, Zhang X, Wu X, Zhou Y, Zhang B, Liu X, Wu X, Li Y, Shen L, Li J.
    Cancer Med; 2020 Sep; 9(17):6225-6233. PubMed ID: 32677196
    [Abstract] [Full Text] [Related]

  • 2. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
    Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH.
    JAMA Oncol; 2018 Jun 01; 4(6):814-820. PubMed ID: 29710216
    [Abstract] [Full Text] [Related]

  • 3. Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review.
    Tan S, Chen P, Ji J, Guo S, Yu D, Asakawa T, Zhou Y, Abe M, Zong L.
    Dis Markers; 2018 Jun 01; 2018():1368617. PubMed ID: 30224936
    [Abstract] [Full Text] [Related]

  • 4. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Woźniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA, Limon J.
    BMC Cancer; 2012 Mar 22; 12():107. PubMed ID: 22439647
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.
    Ann Oncol; 2016 Sep 22; 27(9):1794-9. PubMed ID: 27371698
    [Abstract] [Full Text] [Related]

  • 6. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.
    Tsai HJ, Shan YS, Yang CY, Hsiao CF, Tsai CH, Wang CC, Lin MT, Ting CF, Chan DC, Chen TH, Yen CC, Chen YY, Lin HY, Yeh TS, Ho CL, Shieh TY, Bai LY, Hsu JT, Chen IS, Chen LT, Yeh CN, Taiwan Cooperative Oncology Group (TCOG) GIST Study Group.
    BMC Cancer; 2024 Jul 11; 24(1):828. PubMed ID: 38992597
    [Abstract] [Full Text] [Related]

  • 7. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J, Wang S, Wang R, Wang SY, Han Q, Xu HT, Yang P, Liu Y.
    Pathol Oncol Res; 2020 Jan 11; 26(1):91-100. PubMed ID: 31758409
    [Abstract] [Full Text] [Related]

  • 8. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
    Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD.
    Lancet Oncol; 2013 Nov 11; 14(12):1175-82. PubMed ID: 24140183
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.
    J Clin Oncol; 2012 Jul 01; 30(19):2401-7. PubMed ID: 22614970
    [Abstract] [Full Text] [Related]

  • 10. An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.
    Gheysen M, Vander Borght S, Lehnert S, Vanslembrouck R, Vanden Bempt I, Schöffski P.
    Oncol Res Treat; 2020 Jul 01; 43(9):470-473. PubMed ID: 32640452
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
    Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H.
    Eur J Cancer; 2016 Jul 01; 61():94-101. PubMed ID: 27156227
    [Abstract] [Full Text] [Related]

  • 15. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY, Chen LT, Chen JS.
    Oncotarget; 2017 Jul 04; 8(27):44121-44130. PubMed ID: 28487491
    [Abstract] [Full Text] [Related]

  • 16. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep 04; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

  • 17. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S.
    Clin Cancer Res; 2019 Dec 15; 25(24):7287-7293. PubMed ID: 31471313
    [Abstract] [Full Text] [Related]

  • 18. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
    Serrano C, Vivancos A, López-Pousa A, Matito J, Mancuso FM, Valverde C, Quiroga S, Landolfi S, Castro S, Dopazo C, Sebio A, Virgili AC, Menso MM, Martín-Broto J, Sansó M, García-Valverde A, Rosell J, Fletcher JA, George S, Carles J, Arribas J.
    BMC Cancer; 2020 Feb 05; 20(1):99. PubMed ID: 32024476
    [Abstract] [Full Text] [Related]

  • 19. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
    Blanke CD, Rankin C, Corless C, Eary JF, Mulder K, Okuno SH, George S, Heinrich M.
    Oncologist; 2015 Dec 05; 20(12):1353-4. PubMed ID: 26576593
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I, Park JH, Choi YJ, Jo J, Ryu JS, Ryu MH.
    Br J Cancer; 2013 Oct 29; 109(9):2309-15. PubMed ID: 24084771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.